封面
市场调查报告书
商品编码
1268544

全球干眼病市场 (2023-2032)

Global Dry Eye Disease Market Forecast 2023-2032

出版日期: | 出版商: Inkwood Research | 英文 237 Pages | 商品交期: 2-3个工作天内

价格

在 2023 年至 2032 年的预测期内,全球干眼病市场规模预计将以 5.11% 的复合年增长率增长。 有前途的干眼症产品的推出、新的干眼症诊断技术的引入以及各个年龄段干眼症发病率的增加正在推动市场的增长。

本报告研究了全球干眼病市场,并提供了全面的信息,包括市场动态、市场分析和竞争格局。

内容

第一章研究范围与研究方法

  • 调查目的
  • 调查方法
  • 假设和限制

第 2 章执行摘要

  • 市场规模/估计
  • 市场概览
  • 调查范围
  • 危机情景分析
  • 主要市场调查结果
    • 空气污染是眼病的主要原因
    • COVID-19,许多干眼症的病因
    • 亚洲人患干眼症的风险较高
    • 看屏幕时间过长导致干眼症状

第三章市场动态

  • 主要驱动力
    • 引入新的干眼症诊断技术
    • 推出用于治疗干眼症的有前途的管线产品
    • 干眼症在各个年龄段的发病率和流行率都在上升
  • 主要製约因素
    • 副作用风险
    • 替代疗法
    • 昂贵的专业产品和復杂的报销场景

第四章重点分析

  • 母市场分析
  • 主要市场趋势
  • 波特的五力分析
    • 买家力量
    • 供应商的力量
    • 备选方案
    • 新人
    • 行业竞争
  • 规划增长前景
  • 市场成熟度分析
  • 市场集中度分析
  • 价值链分析
    • 研究与开发
    • 製造业
    • 经销商
    • 售后监控

第 5 章市场:按类型

  • 非处方药
  • 处方药

第 6 章市场:按产品分类

  • 抗炎药
    • 环孢菌素
    • 皮质类固醇
    • 其他抗炎药
  • 人工泪液
  • 朋克焦油塞
  • 秘教
  • 其他

第 7 章市场:按分销渠道

  • 医院药房
  • 独立药房和药店
  • 在线药店

第八章区域分析

  • 北美
  • 欧洲
  • 亚太地区
  • 世界其他地区

第9章竞争格局

  • 重大战略发展
    • 併购
    • 产品发布和开发
    • 合作伙伴关係和合同
    • 业务扩张和销售
  • 公司简介
    • AFT PHARMACEUTICALS
    • ALCON
    • Allergan PLC(ABBVIE收购)
    • BAUSCH HEALTH COMPANIES INC
    • JOHNSON & JOHNSON
    • LUMENIS
    • NOVALIQ GMBH
    • NOVARTIS AG
    • OASIS MEDICAL
    • OTSUKA PHARMACEUTICAL CO LTD
    • SANTEN PHARMACEUTICAL CO LTD
    • SENTISS PHARMA PRIVATE LIMITED
    • SUN PHARMACEUTICAL INDUSTRIES LTD
    • TEVA PHARMACEUTICAL INDUSTRIES LTD
    • VISUFARMA
Product Code: 39637

KEY FINDINGS

The global dry eye disease market is forecasted to record a CAGR of 5.11% during the projected period of 2023-2032. The market growth is ascribed to factors such as the launch of promising pipeline products for dry eye disease, the introduction of new diagnostic techniques for dry eye disease, and the increasing incidence of dry eye among different age groups.

MARKET INSIGHTS

Dry eye is a chronic syndrome, progressive depending on the severity and cause. It is a condition when a person does not have tears to lubricate their eyes. Tears are a vital part of maintaining good eye health and assist in ensuring good vision. The syndrome is typically witnessed among older people. However, it is also becoming common among people who spend long hours in front of the computer.

The accurate diagnosis of dry eye disease is pivotal. Whether it is a practice focusing on a subspecialty, such as glaucoma and retina, or a primary anterior segment practice, the symptoms and signs of dry eye disease are widespread across modern lifestyles. Technological advancements are being made in the field of ophthalmology. Leading firms operating in the market continually concentrate on developing novel therapeutics and diagnostics, as well. For instance, TearScience, a subsidiary of Johnson & Johnson, introduced the latest diagnostic system for dry eye disease in the market, named LipiView II Ocular Surface Interferometer.

REGIONAL INSIGHTS

The global dry eye disease market growth evaluation entails the assessment of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecasting years due to the increasing number of ophthalmologists in countries like China, India, and Japan, providing good treatment and diagnostic services for ophthalmic conditions and the growing ophthalmic education.

COMPETITIVE INSIGHTS

Significant competition exists between key market players for the development of a new treatment for dry eye disease. The highly sustainable competitive advantages through innovation are likely to intensify rivalry among firms. Besides, solid strategies are anticipated to raise the competition in the market studied.

Some of the top companies operating in the market are Johnson & Johnson, Allergan PLC (Acquired by Abbvie), Bausch Health Companies Inc, etc.

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
    • 2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
    • 2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
    • 2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
    • 3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
    • 3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. RISK OF SIDE EFFECTS
    • 3.2.2. SUBSTITUTE THERAPIES
    • 3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO

4. KEY ANALYTICS

  • 4.1. PARENT MARKET ANALYSIS
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. GROWTH PROSPECT MAPPING
  • 4.5. MARKET MATURITY ANALYSIS
  • 4.6. MARKET CONCENTRATION ANALYSIS
  • 4.7. VALUE CHAIN ANALYSIS
    • 4.7.1. RESEARCH AND DEVELOPMENT
    • 4.7.2. MANUFACTURING
    • 4.7.3. DISTRIBUTORS
    • 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

  • 5.1. OTC
  • 5.2. PRESCRIPTION

6. MARKET BY PRODUCT

  • 6.1. ANTI-INFLAMMATORY DRUGS
    • 6.1.1. CYCLOSPORINE
    • 6.1.2. CORTICOSTEROID
    • 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
  • 6.2. ARTIFICIAL TEARS
  • 6.3. PUNCTAL PLUGS
  • 6.4. SECRETAGOGUES
  • 6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

  • 7.1. HOSPITAL PHARMACIES
  • 7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
  • 7.3. ONLINE PHARMACIES

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
    • 8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
    • 8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
    • 8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
    • 8.1.6. COUNTRY ANALYSIS
      • 8.1.6.1. UNITED STATES
      • 8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.1.6.2. CANADA
      • 8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
    • 8.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
    • 8.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
    • 8.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
    • 8.2.6. COUNTRY ANALYSIS
      • 8.2.6.1. UNITED KINGDOM
      • 8.2.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.2. GERMANY
      • 8.2.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.3. FRANCE
      • 8.2.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.4. ITALY
      • 8.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.5. BELGIUM
      • 8.2.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.6. SPAIN
      • 8.2.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.7. POLAND
      • 8.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.2.6.8. REST OF EUROPE
      • 8.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
    • 8.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
    • 8.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
    • 8.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
    • 8.3.6. COUNTRY ANALYSIS
      • 8.3.6.1. CHINA
      • 8.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.2. JAPAN
      • 8.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.3. INDIA
      • 8.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.4. SOUTH KOREA
      • 8.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.5. INDONESIA
      • 8.3.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.6. THAILAND
      • 8.3.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.7. AUSTRALIA & NEW ZEALAND
      • 8.3.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.3.6.8. REST OF ASIA-PACIFIC
      • 8.3.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
    • 8.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
    • 8.4.4. REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
    • 8.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
    • 8.4.6. REGIONAL ANALYSIS
      • 8.4.6.1. LATIN AMERICA
      • 8.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
      • 8.4.6.2. MIDDLE EAST AND AFRICA
      • 8.4.6.2.1. MIDDLE EAST AND AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. AFT PHARMACEUTICALS
    • 9.2.2. ALCON
    • 9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 9.2.4. BAUSCH HEALTH COMPANIES INC
    • 9.2.5. JOHNSON & JOHNSON
    • 9.2.6. LUMENIS
    • 9.2.7. NOVALIQ GMBH
    • 9.2.8. NOVARTIS AG
    • 9.2.9. OASIS MEDICAL
    • 9.2.10. OTSUKA PHARMACEUTICAL CO LTD
    • 9.2.11. SANTEN PHARMACEUTICAL CO LTD
    • 9.2.12. SENTISS PHARMA PRIVATE LIMITED
    • 9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
    • 9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 9.2.15. VISUFARMA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE
  • TABLE 2: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 4: GLOBAL OTC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: GLOBAL OTC MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 6: GLOBAL PRESCRIPTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: GLOBAL PRESCRIPTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 8: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 10: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 11: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 12: GLOBAL CYCLOSPORINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 13: GLOBAL CYCLOSPORINE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 14: GLOBAL CORTICOSTEROID MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 15: GLOBAL CORTICOSTEROID MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 16: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 17: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 18: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 19: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 20: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 21: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 22: GLOBAL SECRETAGOGUES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 23: GLOBAL SECRETAGOGUES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 24: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 25: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 26: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 27: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 28: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 29: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 30: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 31: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 32: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 33: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 34: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 35: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 36: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 37: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 38: NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
  • TABLE 39: KEY PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
  • TABLE 40: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 41: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 42: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
  • TABLE 43: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
  • TABLE 44: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 45: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 46: ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
  • TABLE 47: KEY PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET
  • TABLE 48: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 49: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 50: REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
  • TABLE 51: KEY PLAYERS OPERATING IN REST OF WORLD DRY EYE DISEASE MARKET
  • TABLE 52: LIST OF MERGERS & ACQUISITIONS
  • TABLE 53: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 54: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 55: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
  • FIGURE 4: GROWTH PROSPECT MAPPING FOR EUROPE
  • FIGURE 5: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
  • FIGURE 6: GROWTH PROSPECT MAPPING FOR MEXICO
  • FIGURE 7: MARKET MATURITY ANALYSIS
  • FIGURE 8: MARKET CONCENTRATION ANALYSIS
  • FIGURE 9: VALUE CHAIN ANALYSIS
  • FIGURE 10: GLOBAL DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
  • FIGURE 11: GLOBAL DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)
  • FIGURE 12: GLOBAL DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)
  • FIGURE 13: GLOBAL DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022
  • FIGURE 14: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
  • FIGURE 15: GLOBAL DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022
  • FIGURE 16: GLOBAL DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)
  • FIGURE 17: GLOBAL DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)
  • FIGURE 18: GLOBAL DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
  • FIGURE 19: GLOBAL DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)
  • FIGURE 20: GLOBAL DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)
  • FIGURE 21: GLOBAL DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)
  • FIGURE 22: GLOBAL DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)
  • FIGURE 23: GLOBAL DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
  • FIGURE 24: GLOBAL DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
  • FIGURE 25: GLOBAL DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)
  • FIGURE 26: GLOBAL DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
  • FIGURE 27: NORTH AMERICA DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 28: UNITED STATES DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 29: CANADA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 30: EUROPE DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 31: UNITED KINGDOM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 32: GERMANY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 33: FRANCE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 34: ITALY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 35: BELGIUM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 36: SPAIN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 37: POLAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 38: REST OF EUROPE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 39: ASIA-PACIFIC DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN%)
  • FIGURE 40: CHINA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 41: JAPAN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 42: INDIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 43: SOUTH KOREA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 44: INDONESIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 45: THAILAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 46: VIETNAM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 47: AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 48: REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 49: REST OF WORLD DRY EYE DISEASE MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 50: LATIN AMERICA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 51: MIDDLE EAST & AFRICA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)